Potent kinase inhibitors from the Merck KGaA OGHL: Novel hits against Trypanosoma brucei with potential for repurposing
PLOS Neglected Tropical Diseases · 2025
DOI: 10.1371/journal.pntd.0013719 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2025. Verfasst von Darline Dize und 6 weiteren Autor:innen. Beteiligte Einrichtung: Antimicrobial and Biocontrol Agents Unit (AmBcAU), Department of Biochemistry, Faculty of Science, University of Yaoundé 1, Yaoundé, Cameroon. Hauptthemen laut MEDLINE: Trypanosoma brucei brucei, Protein Kinase Inhibitors, Drug Repositioning, Trypanocidal Agents. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
African trypanosomiasis remains a critical public health concern, with over 55 million people still at risk of infection. There are several issues associated with the current therapies including toxicity and resistance, which represent the main bottleneck of trypanosomiasis control. Thus, it is urgent to develop novel therapeutic tools with distinct mechanisms of action. The in vitro phenotypic screening of the Merck KGaA Darmstadt German Open Global Health Library (OGHL) against Trypanosoma brucei brucei yielded three potent kinase inhibitors belonging to different chemical series: a phenylcarbonylacrylamide (OGHL00006); a 2,4-di(phenylamino)pyrimidine (OGHL00133); and a 3-(triazol-4-yl)-7-azaindole (OGHL00169). They exhibited low micromolar to nanomolar median inhibitory concentrations (IC 50 values of 0.6 µM, 0.007 µM, and 0.25 µM, respectively) and good selectivity when tested on Vero cells (SI > 2). OGHL00006 and OGHL00169 induced a rapid and irreversible growth arrest of T. b. brucei within 4–24 hours of incubation. Interestingly, these two hits have also been reported to display antiplasmodial and/or anthelminthic activities, hinting at a similar mechanism of action across multiple species. Given the significant sequence similarities between the human and trypanosome kinomes, we rationalized the putative mechanisms of action for the identified hits through comparative modeling of protein–ligand complexes. This study suggests promising avenues for drug and/or target repurposing against trypanosomiasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Antimicrobial and Biocontrol Agents Unit (AmBcAU), Department of Biochemistry, Faculty of Science, University of Yaoundé 1, Yaoundé, Cameroon.
- Faculty of Chemistry and Pharmacy, Institute of Pharmaceutical Sciences, University of Freiburg, Freiburg, Germany.
- Department of Drug Discovery, Advanced Research and Health Innovation Hub (ARHIH), Yaoundé, Cameroon.
ORCID-Profile: Fabrice F Boyom
Zitieren
APA
Dize, D., Moumbock, A. F. A., Tchuenguia, V. C., Bougnogolo, G. Y., Nana, F. S. B., Monkam, S. D. W., & Boyom, F. F. (2025). Potent kinase inhibitors from the Merck KGaA OGHL: Novel hits against Trypanosoma brucei with potential for repurposing. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0013719
Vancouver
Dize D, Moumbock AFA, Tchuenguia VC, Bougnogolo GY, Nana FSB, Monkam SDW, et al. Potent kinase inhibitors from the Merck KGaA OGHL: Novel hits against Trypanosoma brucei with potential for repurposing. PLOS Neglected Tropical Diseases. 2025. doi:10.1371/journal.pntd.0013719
BibTeX
@article{Dize2025,
author = {Dize, Darline and Moumbock, Aurélien F A and Tchuenguia, Vianey C and Bougnogolo, Germaine Y and Nana, Fride S B and Monkam, Sandra D W and Boyom, Fabrice F},
title = {Potent kinase inhibitors from the Merck KGaA OGHL: Novel hits against Trypanosoma brucei with potential for repurposing},
journal = {PLOS Neglected Tropical Diseases},
year = {2025},
doi = {10.1371/journal.pntd.0013719}
}
EUVIMED